Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Biomea Fusion (Nasdaq: BMEA) will deliver an oral presentation of Week 52 long-term follow up data for icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles on Dec 3-6, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA) will deliver an oral presentation of Week 52 long-term follow up data for icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles on Dec 3-6, 2025. The oral talk (Abstract #0062COVALENT-111) is titled "Durable Glycemic and C-Peptide Improvements with Icovamenib, a Menin Inhibitor Targeting β-Cell Restoration in Insulin-Deficient Type 2 Diabetes" and is scheduled for Dec 5, 2025, 6:15 pm–7:45 pm PST. Biomea noted it is one of six oral presentations at the meeting and said poster and presentation materials will be available on the company website.
Details
News Market Reaction – BMEA
On Dec 2, the first trading day after this news, BMEA closed 5.22% below the previous close.
Data tracked by StockTitan Argus for the Dec 2 session.
Key Figures
- Week 52 follow-up
- Week 52
- Long-term icovamenib follow-up data in insulin-deficient type 2 diabetes
- Congress dates
- December 3–6, 2025
- 23rd WCIRDC meeting in Los Angeles
- Oral presentation count
- 6 oral presentations
- Icovamenib talk is one of six oral presentations at WCIRDC
- Presentation window
- 6:15 pm–7:45 pm PST
- Scheduled oral presentation time on December 5, 2025
- Price change
- 14.93%
- Pre-news 24h price change for BMEA
- 52-week range high
- 6.44
- 52-week high price before this news
- 52-week range low
- 0.8719
- 52-week low price before this news
- Market cap
- $108,883,604
- Market capitalization prior to this announcement
Historical Context
-
KOL interview and WCIRDC presentation on menin inhibitors and icovamenib.
-
COVALENT-111 data showing durable glycemic and C-peptide improvements at week 52.
-
Announcement of WCIRDC oral presentation for week 52 icovamenib follow-up data.
-
Inducement stock option grant to a new employee under 2023 plan.
-
Planned participation in early December investor healthcare conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
c-peptide medical
menin inhibitor medical
β-cell medical
type 2 diabetes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress showcases cutting-edge developments from both emerging investigators and world-renowned leaders.
“We are delighted to present our Week 52 long-term follow up data at WCIRDC, a meeting renowned for showcasing exciting advances in diabetes and metabolic research,” said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. “Being one of only six oral presentations this year speaks to the interest in icovamenib as a potential paradigm shift in the treatment of type 2 diabetes. Insulin-deficient diabetes remains an underserved population with limited therapeutic options, and icovamenib is potentially a novel treatment option for these patients.”
Oral Presentation Abstract #0062
COVALENT-111: Durable Glycemic and C-Peptide Improvements with Icovamenib, a Menin Inhibitor Targeting β-Cell Restoration in Insulin-Deficient Type 2 Diabetes
Presentation Time
Oral Presentation: December 5, 2025, from 6:15 pm – 7:45 pm PST
Please find a link here to our website where the poster and presentations will be available.
About Icovamenib
Icovamenib is an investigational, orally bioavailable, potent, and selective covalent inhibitor of menin. The proposed mechanism of action for icovamenib in diabetes is selective and partial inhibition of menin, a regulator of beta cell quantity and function, thereby enabling the proliferation, preservation, and reactivation of a patient’s own healthy, functional, insulin-producing beta cells. As the first non-chronic therapy for T2D, icovamenib could become an important addition to the diabetes treatment landscape once it has successfully completed its ongoing clinical studies.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at www.biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.